Investigational Drug Services (IDS) The Investigational Drug Service (IDS) Pharmacy was established at the University of Pittsburgh Cancer Institute (UPCI) in 1986 to coordinate all pharmacy procedures associated with oncology clinical research protocols.
The specific aims of IDS are to 1) Review protocols (pre-approval process), assist with protocol implementation, and coordinate drug management and investigational drug supply; 2) Make clinical recommendations for drug therapy, provide dose calculations and monitoring plans, and manage adverse events; 3) Assist in writing medication administration and delivery section of protocols; and 4) Provide experiential education opportunities for clinical pharmacists in training at the University of Pittsburgh and Duquesne University. The goal of the IDS is to ensure that the procurement, receipt, storage, accountability, preparation, dispensing, labeling, and shipping of investigational agents are performed in accordance with all state and federal laws. Clinical recommendations for drug therapy, monitoring plans for a treatment regimen, managing adverse events, and dose calculations are performed with respect to the treatment of patients who have agreed to participate in a clinical research protocol. Moreover, the IDS works with physicians, nurses, and other clinical research personnel in order to provide optimal care for patients with cancer. The IDS pharmacy employs two pharmacists and one pharmacy technician. In addition to the IDS personnel, the UPMC Shadyside-Hillman Cancer Center Clinic Pharmacy works with the IDS and has ten full-time pharmacy technicians, twelve full-time pharmacists, and 2 part-time pharmacists. These individuals assist in treating patients enrolled in protocol treatments mainly through checking eligibility for the trials and treatments, entering chemotherapy orders, and mixing chemotherapy. The IDS reviews all approved IRB protocols, standard chemotherapy and protocol regimens, supportive care regimens (antiemetics and other premedications), and investigational drug policies and procedures. The IDS pharmacy prepares, labels, and dispenses all investigational medications and maintains accurate and complete drug accountability records for all investigational agents. For oral agents, an IDS pharmacist counsels each patient receiving an investigational drug dispensed for home administration at the Hillman Cancer Center. This process occurs with the first dispense, along with any dose changes (dose reduction or dose escalation). Throughout the entire network, the IDS provides oversight and monitoring for all clinical trial related activities. In the current project period members of six UPCI Research Programs used IDS.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-28
Application #
9114514
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
28
Fiscal Year
2016
Total Cost
$25,732
Indirect Cost
$9,023
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Weir, Mark C; Shu, Sherry T; Patel, Ravi K et al. (2018) Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol 13:1551-1559
Chakraborty, Souvik; Jiang, Chang; Gau, David et al. (2018) Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells. Br J Cancer 119:1106-1117
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Song, Xinxin; Lee, Dae-Hee; Dilly, Ashok-Kumar et al. (2018) Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex. Mol Cancer Res 16:1077-1091
Chen, Dongshi; Tong, Jingshan; Yang, Liheng et al. (2018) PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc Natl Acad Sci U S A 115:3930-3935
Teng, Yaqun; Yadav, Tribhuwan; Duan, Meihan et al. (2018) ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB. Nat Commun 9:4115
Nguyen, Nghi C; Yee, Melissa K; Tuchayi, Abuzar M et al. (2018) Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol 8:18
Hartmaier, R J; Trabucco, S E; Priedigkeit, N et al. (2018) Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 29:872-880
Palliyaguru, Dushani L; Yuan, Jian-Min; Kensler, Thomas W et al. (2018) Isothiocyanates: Translating the Power of Plants to People. Mol Nutr Food Res 62:e1700965

Showing the most recent 10 out of 1187 publications